Increasing the Effectiveness and Sustainable Outcomes of IME Through Collaborative Grants Programs
Track: Full Session (30 minutes)
Since 2012, the Pfizer Global Medical Grants team (formerly Independent Grants for Learning & Change) has demonstrated a new model for providing commercial support of IME. Pfizer has collaborated with stakeholder organizations that share similar goals in improving specific aspects of patient care. Mayo Clinic and the National Comprehensive Cancer Network® (NCCN®) are two organizations that have worked alongside with Pfizer to solicit and award grants in specific areas of clinical practice. The collaborative-RFP model consistently results in grant applications that far surpass the intensity and quality of typical grant requests that Pfizer receives outside of these collaborations. Stakeholder organizations outside of the pharmaceutical industry bring credibility, expertise, broad networks and outreach, and innovation and excitement from new grant applicant organizations. Other organizations that have participated with Pfizer in this model include The Joint Commission, the American Academy of Pediatrics, the International Atherosclerosis Society, and the University of California San Francisco. This session will explain the collaborative-grants model used by Pfizer for the last 5 years and provide practical tips and advice for others who may want to participate in or implement a similar model. Specific examples of grants funded and the reasons for their success will be explored.